Analysis of clinical value of calcium carbonate combined with disuzumab in the treatment of postmenopausal osteoporosis patients
Objective To explore the clinical value of calcium carbonate combined with disuzumab in the treatment of postmenopausal osteoporosis.Methods 74 postmenopausal patients with osteoporosis were randomly divided into control group and study group with 37 cases in each group.The control group was treated with calcium carbonate,and the study group was treated with calcium carbonate combined with desumab.The clinical effect,bone mineral density and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was significantly higher than that of the control group,and the difference was statistically significant(P＜0.05).Hip bone mineral density(0.78±0.13)g/cm3 and lumbar bone mineral density(0.87±0.16)g/cm3 in the study group after treatment were significantly higher than those in the control group(0.60±0.07)g/cm3 and(0.71±0.12)g/cm3,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The application of calcium carbonate combined with disumab in the treatment of postmenopausal osteoporosis patients is effective,can improve the bone mineral density of patients,less side effects,high safety factor,and can ensure the safety and health of patients.
NETL
NSTL
万方数据
